MARKET

CTOR

CTOR

Citius Oncology, Inc.
NASDAQ
0.9040
-0.0028
-0.31%
Closed 16:10 05/11 EDT
OPEN
0.8800
PREV CLOSE
0.9068
HIGH
0.9040
LOW
0.8221
VOLUME
284.70K
TURNOVER
0
52 WEEK HIGH
6.19
52 WEEK LOW
0.4912
MARKET CAP
79.80M
P/E (TTM)
-2.9152
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CTOR last week (0504-0508)?
Weekly Report · 22h ago
Citius Oncology Secures New Financing to Support LYMPHIR
TipRanks · 5d ago
Press Release: Citius Oncology, Inc. Secures Up -2-
Dow Jones · 6d ago
Press Release: Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR(R) Commercialization
Dow Jones · 6d ago
Weekly Report: what happened at CTOR last week (0427-0501)?
Weekly Report · 05/04 10:25
Citius Oncology Begins First European Expansion of LYMPHIR
TipRanks · 04/29 22:15
Citius Oncology announces initial shipment of LYMPHIR to Europe
TipRanks · 04/29 14:53
Citius Oncology Faces Nasdaq Non-Compliance, Delisting Risk Looms
TipRanks · 04/28 22:30
More
About CTOR
Citius Oncology, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapies. The Company’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the diphtheria toxin (DT) fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death.

Webull offers Citius Oncology Inc stock information, including NASDAQ: CTOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTOR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTOR stock methods without spending real money on the virtual paper trading platform.